Table 1.

Treatment recommendations for RSV bronchiolitis in the outpatient setting

Medicine
Antibiotics	Not recommended	Antibiotics have no effect on the course of acute bronchiolitis [92], nor do they prevent persistent respiratory symptoms in the postacute bronchiolitis phase [51]. Antibiotics should only be used in case of concurrent bacterial infection.
Bronchodilators	Not recommended	Bronchodilators do not reduce the need for hospitalization nor shorten the length of illness [93].
Inhaled steroids	Not recommended	Inhaled corticosteroids have no effect on the course of acute bronchiolitis, nor are they effective in preventing recurrent wheeze [52,94]
Epinephrine	Not routinely recommended	Nebulised epinephrine may have a modest effect among outpatients on the risk of hospital admission in the early stages of disease [95]
Systemic steroids	Not recommended	Systemic corticosteroids have no or minimal effect on the course of acute bronchiolitis [94]
Chest physiotherapy	Not routinely recommended	There is low-certainty evidence that chest physiotherapy may result in mild to moderate improvement of disease severity for those with moderately severe bronchiolitis in outpatient settings [96]
Hypertonic saline	Not routinely recommended	Nebulised hypertonic saline may slightly reduce the risk of hospitalization amongst outpatients [97]
RSV-specific monoclonal antibodies	Not recommended	RSV monoclonal antibodies should not be used to treat acute viral bronchiolitis. They are used for RSV prevention.
Leukotriene receptor agonists	Not recommended	Montelukast has no effect on the course of acute bronchiolitis nor on postbronchiolitis wheeze [98]